Developing a tool to improve the safety of biotherapeutic drugs
Official title: Specificity Screening Drug Development Tool for Biotherapeutic Safety
Funded at Integral Molecular · NIH-11002039 · Data updated 2026-11-12
This study is working on a new way to make sure that certain advanced treatments for diseases, like monoclonal antibodies and CAR-T cell therapies, are safer by using a special tool to better understand how they interact with the body, which could help prevent problems before they happen.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Integral Molecular NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $917,454 |
| NIH project number | 1SB1GM156044-01 |
| Project ID | NIH-11002039 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who may benefit from monoclonal antibodies or CAR-T cell therapies.
✕Less likely to help
Patients who are not candidates for biotherapeutic treatments or those with conditions unrelated to the therapies being studied may not receive any benefit.
What this research studies
This research focuses on enhancing the safety of biotherapeutic drugs, particularly monoclonal antibodies and CAR-T cell therapies, by developing a new tool for specificity profiling. The current methods for assessing the safety of these drugs are often inadequate, leading to high rates of preclinical failures. The study aims to utilize a novel technology called the Membrane Proteome Array, which can better predict off-target effects by analyzing a wide range of human proteins in their natural state. This approach could significantly improve the drug development process and reduce risks associated with biotherapeutics.
Why it matters
Potential benefit: If successful, this research could lead to safer biotherapeutic drugs with fewer adverse effects for patients.
How similar studies have gone: Previous research has shown that improved specificity profiling can enhance drug safety, indicating that this approach has the potential for success.
Where this research is happening
-
Integral Molecular
Philadelphia, United States Active
Researchers
- Principal investigator: Doranz, Benjamin J — Integral Molecular
- Study coordinator: Doranz, Benjamin J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.